Cargando…
Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial
OBJECTIVE: To evaluate whether probiotic supplementation attenuates gut-dysbiosis in neonates with congenital gastrointestinal surgical conditions (CGISC). METHODS: Sixty-one neonates (≥35 weeks gestation) with CGISC were randomised to receive daily supplementation with a triple-strain bifidobacteri...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722408/ https://www.ncbi.nlm.nih.gov/pubmed/34980887 http://dx.doi.org/10.1038/s41390-021-01884-x |
_version_ | 1784625519613968384 |
---|---|
author | Rao, Shripada Esvaran, Meera Chen, Liwei Keil, Anthony D. Gollow, Ian Simmer, Karen Wemheuer, Bernd Conway, Patricia Patole, Sanjay |
author_facet | Rao, Shripada Esvaran, Meera Chen, Liwei Keil, Anthony D. Gollow, Ian Simmer, Karen Wemheuer, Bernd Conway, Patricia Patole, Sanjay |
author_sort | Rao, Shripada |
collection | PubMed |
description | OBJECTIVE: To evaluate whether probiotic supplementation attenuates gut-dysbiosis in neonates with congenital gastrointestinal surgical conditions (CGISC). METHODS: Sixty-one neonates (≥35 weeks gestation) with CGISC were randomised to receive daily supplementation with a triple-strain bifidobacterial probiotic (n = 30) or placebo (n = 31) until discharge. Stool microbiota was analysed using 16S ribosomal RNA gene sequencing on samples collected before (T1), 1 week (T2), and 2 weeks (T3) after supplementation and before discharge (T4). The primary outcome was the sum of the relative abundance of potentially pathogenic families of Clostridiaceae, Enterobacteriaceae, Enterococcaceae, Pseudomonaceae, Staphylococcaeae, Streptococcaceae, and Yersiniaceae at T3. RESULTS: The median gestational age [38 weeks (IQR: 37.1–38.9)] was similar in both groups. The probiotic group had lower rates of caesarean deliveries (40% versus 70%, p = 0.02). The relative abundance of potentially pathogenic families was lower in the probiotic group compared to placebo at T3 [(median: 50.4 (IQR: 26.6–67.6) versus 67.1 (IQR: 50.9–96.2); p = 0.04). Relative abundance of Bifidobacteriaceae was higher in the probiotic group at T3 [(median: 39.8 (IQR: 24.9–52.1) versus 0.03 (IQR 0.02–2.1); p < 0.001). Stratified analysis continued to show a higher abundance of Bifidobacteriaceae in the probiotic group, irrespective of the mode of delivery. CONCLUSIONS: Probiotic supplementation attenuated gut dysbiosis in neonates with CGISC. TRIAL REGISTRATION: http://www.anzctr.org.au (ACTRN12617001401347). IMPACT: Probiotic supplementation attenuates gut dysbiosis and improves stool short-chain fatty acid levels in neonates with congenital gastrointestinal surgical conditions. This is the second pilot RCT of probiotic supplementation in neonates with congenital gastrointestinal conditions. These findings will pave the way for conducting multicentre RCTs in this area. |
format | Online Article Text |
id | pubmed-8722408 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-87224082022-01-04 Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial Rao, Shripada Esvaran, Meera Chen, Liwei Keil, Anthony D. Gollow, Ian Simmer, Karen Wemheuer, Bernd Conway, Patricia Patole, Sanjay Pediatr Res Clinical Research Article OBJECTIVE: To evaluate whether probiotic supplementation attenuates gut-dysbiosis in neonates with congenital gastrointestinal surgical conditions (CGISC). METHODS: Sixty-one neonates (≥35 weeks gestation) with CGISC were randomised to receive daily supplementation with a triple-strain bifidobacterial probiotic (n = 30) or placebo (n = 31) until discharge. Stool microbiota was analysed using 16S ribosomal RNA gene sequencing on samples collected before (T1), 1 week (T2), and 2 weeks (T3) after supplementation and before discharge (T4). The primary outcome was the sum of the relative abundance of potentially pathogenic families of Clostridiaceae, Enterobacteriaceae, Enterococcaceae, Pseudomonaceae, Staphylococcaeae, Streptococcaceae, and Yersiniaceae at T3. RESULTS: The median gestational age [38 weeks (IQR: 37.1–38.9)] was similar in both groups. The probiotic group had lower rates of caesarean deliveries (40% versus 70%, p = 0.02). The relative abundance of potentially pathogenic families was lower in the probiotic group compared to placebo at T3 [(median: 50.4 (IQR: 26.6–67.6) versus 67.1 (IQR: 50.9–96.2); p = 0.04). Relative abundance of Bifidobacteriaceae was higher in the probiotic group at T3 [(median: 39.8 (IQR: 24.9–52.1) versus 0.03 (IQR 0.02–2.1); p < 0.001). Stratified analysis continued to show a higher abundance of Bifidobacteriaceae in the probiotic group, irrespective of the mode of delivery. CONCLUSIONS: Probiotic supplementation attenuated gut dysbiosis in neonates with CGISC. TRIAL REGISTRATION: http://www.anzctr.org.au (ACTRN12617001401347). IMPACT: Probiotic supplementation attenuates gut dysbiosis and improves stool short-chain fatty acid levels in neonates with congenital gastrointestinal surgical conditions. This is the second pilot RCT of probiotic supplementation in neonates with congenital gastrointestinal conditions. These findings will pave the way for conducting multicentre RCTs in this area. Nature Publishing Group US 2022-01-03 2022 /pmc/articles/PMC8722408/ /pubmed/34980887 http://dx.doi.org/10.1038/s41390-021-01884-x Text en © Crown 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Clinical Research Article Rao, Shripada Esvaran, Meera Chen, Liwei Keil, Anthony D. Gollow, Ian Simmer, Karen Wemheuer, Bernd Conway, Patricia Patole, Sanjay Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial |
title | Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial |
title_full | Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial |
title_fullStr | Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial |
title_full_unstemmed | Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial |
title_short | Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial |
title_sort | probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial |
topic | Clinical Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722408/ https://www.ncbi.nlm.nih.gov/pubmed/34980887 http://dx.doi.org/10.1038/s41390-021-01884-x |
work_keys_str_mv | AT raoshripada probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial AT esvaranmeera probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial AT chenliwei probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial AT keilanthonyd probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial AT gollowian probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial AT simmerkaren probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial AT wemheuerbernd probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial AT conwaypatricia probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial AT patolesanjay probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial |